Hyderabad-based GVK Bio on 6 November 2014 signed definitive agreement to acquire US-based Vanta Bioscience. The acquisition will enable GVK BIO to offer GLP toxicology services for Pharmaceuticals, Agrochemicals, Nutraceuticals, and Cosmetics
The acquisition is in line with company’s business strategy of being an integrated drug discovery services provider for their customers. The acquisition of Vanta Bioscience further advances the company’s position as it expands its service offering in GLP toxicology.
About GVK BIO
GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization.
The company provides a broad spectrum of integrated services across the R&D and manufacturing value chain with a focus on speed and quality.
Its capabilities include Discovery Services, Contract Manufacturing, Formulations, Informatics and Clinical Development.
The Chief Executive Officer (CEO) of the company is Manni Kantipudi.
About Vanta Bioscience
Vanta Bioscience offers safety and efficacy assessment services for clients in the pharmaceutical, biotech, medical device, cosmetics, agriculture, food supplements, feed additives and chemical industries.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.